Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 12
Submit an article Journal homepage
510
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

Anthony MatoLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USACorrespondence[email protected]
,
Tatyana FeldmanLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Tania ZielonkaLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Arun SingaviLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Gabriella GadalettaLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Kathryn WaksmundzkiLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Pritish BhattacharyyaLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Kar Fai ChowLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Xiao YangLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
David PanushLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Harry AgressLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Maria RosarioLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
,
Christina HowlettLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA;Clinical Assistant Professor, Ernest Mario School of Pharmacy, Rutgers University, Hackensack, NJ, USA
,
Andrew PecoraLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
&
Andre GoyLymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
 show all
Pages 2606-2612 | Received 08 Nov 2012, Accepted 05 Mar 2013, Published online: 15 May 2013

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mark-Alexander Schwarzbich, Tilman Schöning, Martin Cremer, Katharina Lisenko, Anthony D. Ho & Matthias Witzens-Harig. (2016) Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment. Leukemia & Lymphoma 57:7, pages 1723-1726.
Read now
Anupkumar George, Constantine S. Tam & John F. Seymour. (2013) High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?. Leukemia & Lymphoma 54:12, pages 2575-2576.
Read now

Articles from other publishers (8)

Charanpreet Singh, Pankaj Malhotra, Aditya Jandial, Arihant Jain, Deepesh Lad, Alka Khadwal, Amanjit Bal, Ashim Das, BR Mittal & Gaurav Prakash. (2022) Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial). Indian Journal of Hematology and Blood Transfusion 39:1, pages 77-84.
Crossref
Takahide Taniguchi, Shoko Nakayama, Hirokazu Tanaka, Shinya Rai, Chikara Hirase, Yasuyoshi Morita, Yoichi Tatsumi, Takashi Ashida, Mitsuhiro Matsuda, Shigeo Hashimoto & Itaru Matsumura. (2022) Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL ‐6 production in lymphoma cells . British Journal of Haematology 198:2, pages 360-372.
Crossref
Kristina Sonnevi, Maria Ljungqvist, Jóel Kristinn Jóelsson, Sara Harrysson, Tove Wästerlid, Per Bernell & Björn Engelbrekt Wahlin. (2021) Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience. eJHaem 2:4, pages 774-784.
Crossref
Alina M. Bischin, Prakash Vishnu, Ruqin Chen, Kevin B. Knopf & David M. Aboulafia. (2019) Quality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 3:4, pages 485-494.
Crossref
Andre Goy. (2018) Reply to H. Tilly et al. Journal of Clinical Oncology 36:9, pages 923-925.
Crossref
Z Yao, L Deng, Z Y Xu-Monette, G C Manyam, P Jain, A Tzankov, C Visco, G Bhagat, J Wang, K Dybkaer, W Tam, E D Hsi, J H van Krieken, M Ponzoni, A J M Ferreri, M B Møller, J N Winter, M A Piris, L Fayad, Y Liu, Y Song, R Z Orlowski, H Kantarjian, L J Medeiros, Y Li, J Cortes & K H Young. (2017) Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32:2, pages 353-363.
Crossref
Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Jennifer J. D. Morrissette & Stephen J. Schuster. (2014) ‘Double-Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. British Journal of Haematology 166:3, pages 369-374.
Crossref
Yasuhiro Oki, Jason R. Westin, Francisco Vega, Hubert Chuang, Nathan Fowler, Sattva Neelapu, Fredrick B. Hagemeister, Peter McLaughlin, Larry W. Kwak, Jorge E. Romaguera, Michelle Fanale, Anas Younes, Maria Alma Rodriguez, Robert Z. Orlowski, Michael Wang, Souzanne T. Ouzounian, Felipe Samaniego & Luis Fayad. (2013) Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. British Journal of Haematology 163:5, pages 611-620.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.